However, our experience from working with breast cancers is that infiltrating CD163+ TAMs are quite frequent, but CD169+ TAMs are not, indicating that only a minority of the CD163+ TAMs (M2-like TAMs) are CD169+ (9, 51). Here, SIGLEC1 is linked to breast carcinoma.